Mobile Site ›

Interpretive Handbook

‹ Back to index | Back to list | More information

Test 88897 :
B-Cell Lymphoma, FISH, Blood or Bone Marrow

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Lymphoid neoplasms are known to be complex and the prognosis and clinical course of patients with lymphoma is highly variable. Genetic abnormalities have emerged as one of the most reliable criteria for categorizing lymphomas. Several chromosome anomalies and variants of these anomalies have been associated with various kinds of lymphoma (see Table).


Common Chromosome Anomalies in B-Cell Lymphomas

Lymphoma Type

Chromosome Abnormality

FISH Probe

Burkitt (pediatric)

8q24.1 rearrangement











Mantle Cell



12p13 rearrangement(1)


17p deletion(2)



8q24.1 rearrangement(2)






18q21 rearrangement(3)






Diffuse large B-cell, Burkitt-like "double-hit"





8q24.1 rearrangement


    reflex: t(8;14)(q24.1;q32)


    reflex: t(8;22)(q24.1;q11.2)


    reflex: t(2;8)(p12;q24.1)


    reflex: 3q27 rearrangement


    reflex: 18q21 rearrangement(3)






18q21 rearrangement(4)


   reflex: t(11;18)(q21;q21)


   reflex: t(14;18)(q32;q21)





Splenic marginal zone

7q deletion


17p deletion



1: CCND2 available upon request if IGH/CCND1 probe is normal

2: TP53 and MYC available for blastoid mantle cell lymphoma only

3: BCL2/IGH available upon request if BCL2 is disrupted

4: BIRC3/MALT1 and IGH/MALT1 available upon request if MALT1 is disrupted


Useful For Suggests clinical disorders or settings where the test may be helpful

Detecting a neoplastic clone associated with the common chromosome abnormalities seen in patients with various B-cell lymphomas


Tracking known chromosome abnormalities and response to therapy in patients with B-cell neoplasms

Interpretation Provides information to assist in interpretation of the test results

A neoplastic clone is detected when the percent of cells with an abnormality exceeds the normal reference range for any given probe.


The absence of an abnormal clone does not rule out the presence of neoplastic disorder.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

This test is not approved by the FDA and it is best used as an adjunct to existing clinical and pathologic information.


Bone marrow is the preferred sample type for this FISH test. If bone marrow is not available, a blood specimen may be used if there malignant cells in the blood specimen (as verified by hematopathology).

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided.

Clinical References Provides recommendations for further in-depth reading of a clinical nature

1. WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues. Edited by SH Swerdlow, E Campo, NL Harris. IARC, Lyon 2008, pp 185-187, 214-217, 220-226, 229-237, 262-278

2. Remstein ED, Kurtin PJ, Buno I, et al: Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol 2000 Sep;110(4):856-862

3. Remstein ED, Kurtin PJ, James CD, et al: Mucosa-associated lymphoid tissue lymphomas with t(11;18) (q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways. Am J Pathol 2002 Jul;161(1):63-71

4. Remstein ED, Dogan A, Einerson RR, et al: The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006 Dec;30(12):1546-1553H636